Maintain MDT position; HOLD with idle trigger ladder and time-based mid-October reassessment ahead of Q2 FY27 catalyst
HOLD is the correct synthesis because the bull/bear evidence is genuinely balanced and the prior decision history is dispositive against both extremes. The aggressive 50% scale-in at $92.60 violates asymmetric risk/reward (2.8% downside vs 5-11% upside), confirmed MACD deterioration, and the binding 9/4 lesson on extended entries. The conservative trim-now thesis ignores the 49-year dividend growth streak, $5.4B FCF covering $3.65B dividend at 1.5x, and intact Golden Cross/200 SMA floor. This is a core defensive holding (0.57 beta, 3%+ yield), not a momentum trade — both sizing extremes mis-size for the actual setup. The $87.50 stop must be honored without hesitation if triggered; the $94.70 upgrade trigger requires MACD confirmation, not speculation.
| Position | Action |
|---|---|
| Upgrading to Overweight post-confirmation | Scale in over 2-3 tranches rather than committing all at once |
| Current position maintenance | Maintain current weight at ~$90 cost basis with 3%+ dividend carry |
| Price between $90-$94.50 consolidation range | Do NOT add — no favorable entry, upside 5-11% vs 2.8% downside to stop is coin flip, not asymmetric |
| Close below $87.50 on volume >15M with 50/200 SMA break | Trim 10-15% (not 30-35%) — carry bid absorbs weakness, no fundamental impairment |
Medtronic is a healthcare bellwether coiled for a breakout with accelerating fundamentals at a discounted forward multiple, positioning itself as a growth story disguised as a defensive through its cardiovascular portfolio expansion, renal denervation leadership, and AI-driven acute care initiatives.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 92.52 | neutral |
| close_50_sma | 88.29 | bullish |
| close_200_sma | 88.42 | bullish |
| rsi | 55.48 | neutral |
| macd | 1.20 | bullish |
| macds | 1.41 | neutral |
| macdh | -0.20 | bearish |
| boll | 92.31 | neutral |
| boll_ub | 94.68 | neutral |
| boll_lb | 89.94 | neutral |
| atr | 2.30 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close below $87.50 on volume >15M (50/200 SMA break)
Then: Downgrade to Underweight; trim 10-15%
Forward P/E of 14.45x represents significant multiple expansion potential
↩ rebuts: “Bear claim that valuation already reflects the good news”
EV: +$7-13 (from ~$92.60 to $98-106) · concedes: MACD histogram is negative at -0.20 and requires monitoring; ~$570M of Q1 revenue was attributable to extra selling week; TAVR CMS expansion does favor Edwards more directly in structural heart; Would prefer clean close above $94.70 on volume before full position; Forward EPS of $6.41 may be ambitious if growth decelerates
MDT at $92.60 is a SELL into strength; the bull case requires everything to go right while the bear case requires only one thing to falter, and technicals are already signaling the next leg lower.
EV: -$84-86 (target price vs current $92.60) · concedes: Clean close above $94.70 on volume >12M AND MACD crossing back above signal; Forward EPS estimates holding flat or rising (not being revised down); Q2 FY27 organic growth (ex-the-extra-week comp) coming in at >8%; Boston Scientific showing signs of structural (not temporary) weakness, OR an MDT-specific catalyst like a major renal denervation data readout
→ vs conservative: Anchoring on inflated 13.7% headline (vs 7.9% organic) misses genuine underlying beat; consensus was modeling only 5% organic before the print, and management raised guidance because the cleaned-up number blew through internal forecasts
→ vs conservative: Forward P/E discount signals compression, not expansion; but analysts are modeling EPS expansion ($6.41 vs $4.06), not the $3.20 contraction the conservative implies; this is a market failure to credit structural improvements
→ vs conservative: Technical deterioration argument is overweighted; MACD cross, RSI cooling, and three failed $94.17 resistance tests are noise when Golden Cross is intact, price above 50 and 200 SMA, and uptrend from $73.15 May low is structurally sound
→ vs conservative: Waiting for chart resolution while competitive landscape hands MDT share on silver platter (BSX down 57%, ISRG down 25%) is poor opportunity cost; the conservative is using caution to justify inaction
→ vs neutral: Waiting for confirmation above $94.70 on 12 million shares to enter ties up 100% of capital for a textbook trigger when dividend yield, accelerating fundamentals, and defensive sector tailwind are present; better to scale in tranches
→ vs neutral: HOLD is a defensible non-decision that leaves real alpha on the table; the compression pattern at resistance with coiled spring setup should be acted upon, not watched as the stock potentially rips to $98 or $100
| vwma | 92.36 | bullish |
Support: 89.94 · 88.29 · 78.66 | Resistance: 94.17 · 94.68 · 100.71
MDT is in a constructive medium-term uptrend (price > 50 SMA > 200 SMA) but is currently coiling at resistance with cooling momentum (negative MACD cross, softening RSI). The 50 SMA (88.29) and 200 SMA (88.42) convergence creates major support, while $94.68 (Bollinger upper band) is the immediate overhead ceiling. A HOLD is warranted pending either a breakout above $94.70 on strong volume or a breakdown below $88.30.
Market Cap
$118.45B
Shares Outstanding (Diluted)
~1.285B
P/E (TTM)
22.81
Forward P/E
14.45
PEG Ratio
1.69
P/B
2.36
EPS (TTM)
$4.06
Forward EPS
$6.41
Dividend Yield
3.07%
Beta
0.574
52-Week High
$106.33
52-Week Low
$73.31
50-Day Average
$88.11
200-Day Average
$89.44
TTM Revenue
$37.54B
Gross Profit
$24.50B
EBITDA
$10.41B
Net Income
$5.23B
Gross Margin
65.3%
Operating Margin
19.33%
Net Margin
13.93%
ROE
10.65%
ROA
5.12%
FCF (TTM)
$5.41B
Operating CF (TTM)
~$7.36B
Quarterly Dividend
~$0.72/share
Total Assets
$93.31B
Total Liabilities
$42.46B
Stockholders' Equity
$50.23B
Goodwill & Intangibles
$53.42B
Tangible Book Value
($3.19B)
Cash & Equivalents
$1.69B
Short-Term Investments
$7.13B
Total Liquidity
$8.82B
Total Debt
$28.15B
Net Debt
$26.41B
Long-Term Debt
$25.57B
Current Debt
$2.54B
Working Capital
$12.59B
Current Ratio
2.07
Debt/Equity
55.4%
Q1 FY27 Revenue
$9.756B
Q1 FY27 Gross Margin
65.0%
Q1 FY27 Operating Income
$1.836B
Q1 FY27 Net Income
$1.470B
Q1 FY27 EPS
$1.14
Q1 FY27 FCF
$1.290B
Q1 FY27 Acquisition
$1.162B
Strengths
Concerns
Medtronic exhibits a high-quality defensive profile with accelerating fundamentals (Q1 FY27 revenue +13.7% YoY, EPS +40.7% YoY), a compelling forward P/E of 14.45x versus TTM 22.81x, $5.4B TTM FCF supporting a 3%+ dividend yield, and low beta (0.57). However, the forward EPS projection of $6.41 carries execution risk, goodwill exposure is elevated at $53.4B, and Net Debt of $26.4B warrants monitoring. With the current price mid-range between 52-week high/low and neutral momentum, HOLD is appropriate - accumulating on weakness toward $73-80 would improve risk/reward, while a decisive breakout above $106 with strong fundamentals would warrant upgrading to BUY.
Macro: The Fed is expected to stay on hold through year-end (4% probability of cut by Dec 2026), supporting defensive names like MDT. US recession probability is low (12%) but rising (+4pp WoW), maintaining soft-landing consensus. Democratic House control is priced at 88%, with a potential Democratic sweep (Senate + House) at 60%, which historically pressures device pricing/Medicare policy. However, recent CMS TAVR coverage expansion signals incremental Medicare decisions are still happening. Gold/silver rallying above $4,300 suggests dovish positioning at the margin despite low cut-probability pricing — watch for hawkish surprise risk.